Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLESS-II: LetibotulinumtoxinA for Glabellar Lines
NCT02677805Phase 3Completed
- Sponsor
- Croma-Pharma
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of letibotulinumtoxinA in glabellar lines, sponsored by Croma-Pharma. Started Mar 2016; status: completed.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT02677805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677805.